W
351.60
6.22 (1.80%)
| Previous Close | 345.38 |
| Open | 343.49 |
| Volume | 533,250 |
| Avg. Volume (3M) | 553,438 |
| Market Cap | 20,923,400,192 |
| Price / Earnings (TTM) | 31.93 |
| Price / Earnings (Forward) | 27.03 |
| Price / Sales | 7.05 |
| Price / Book | 11.40 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 21.56% |
| Operating Margin (TTM) | 32.53% |
| Diluted EPS (TTM) | 10.72 |
| Quarterly Revenue Growth (YOY) | 6.50% |
| Quarterly Earnings Growth (YOY) | 7.00% |
| Total Debt/Equity (MRQ) | 93.13% |
| Current Ratio (MRQ) | 2.11 |
| Operating Cash Flow (TTM) | 762.12 M |
| Levered Free Cash Flow (TTM) | 627.06 M |
| Return on Assets (TTM) | 11.40% |
| Return on Equity (TTM) | 42.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Waters Corporation | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 96.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fundsmith Investment Services Ltd. | 31 Dec 2024 | 1,224,932 |
| Ako Capital Llp | 31 Dec 2024 | 815,379 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 460.00 (Keybanc, 30.83%) | Buy |
| Median | 374.00 (6.37%) | |
| Low | 350.00 (Barclays, -0.46%) | Hold |
| Average | 386.80 (10.01%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 352.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 07 May 2025 | 374.00 (6.37%) | Buy | 345.46 |
| 22 Apr 2025 | 355.00 (0.97%) | Buy | 330.71 | |
| UBS | 07 May 2025 | 360.00 (2.39%) | Hold | 345.46 |
| Barclays | 10 Apr 2025 | 350.00 (-0.46%) | Hold | 314.66 |
| Keybanc | 31 Mar 2025 | 460.00 (30.83%) | Buy | 368.57 |
| JP Morgan | 06 Mar 2025 | 390.00 (10.92%) | Hold | 386.33 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 May 2025 | Announcement | Waters Corporation to Present at the Jefferies Global Healthcare Conference |
| 06 May 2025 | Announcement | Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance |
| 06 May 2025 | Announcement | Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results |
| 08 Apr 2025 | Announcement | Waters Corporation Schedules First Quarter 2025 Earnings Conference Call |
| 01 Apr 2025 | Announcement | Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC |
| 07 Mar 2025 | Announcement | Waters Corporation to Present at the Leerink Partners Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |